{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:45:11Z","timestamp":1792727111139,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T00:00:00Z","timestamp":1408579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T00:00:00Z","timestamp":1408579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/srep06152","type":"journal-article","created":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T09:07:08Z","timestamp":1408612028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma"],"prefix":"10.1038","volume":"4","author":[{"given":"Amanda L.","family":"Hudson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozelle","family":"Harvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Klebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viive M.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,21]]},"reference":[{"key":"BFsrep06152_CR1","unstructured":"WHO. Asbestos: elimination of asbestos-related diseases. Fact sheet No 343, July, 2010)."},{"key":"BFsrep06152_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/oemed-2012-101290","volume":"70","author":"MR Sim","year":"2013","unstructured":"Sim, M. R. A worldwide ban on asbestos production and use: some recent progress, but more still to be done. Occup Environ Med 70, 1\u20132 (2013).","journal-title":"Occup Environ Med"},{"key":"BFsrep06152_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.5694\/mja11.10125","volume":"195","author":"NJ Olsen","year":"2011","unstructured":"Olsen, N. J. et al. Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust 195, 271\u2013274 (2011).","journal-title":"Med J Aust"},{"key":"BFsrep06152_CR4","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21, 2636\u20132644 (2003).","journal-title":"J Clin Oncol"},{"key":"BFsrep06152_CR5","unstructured":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. The Asbestos Diseases Research Institute Place published (2013)."},{"key":"BFsrep06152_CR6","unstructured":"Remon, J. et al. Malignant mesothelioma: New insights into a rare disease. Cancer Treat Rev (2012)."},{"key":"BFsrep06152_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ctrv.2011.01.001","volume":"37","author":"PA Zucali","year":"2011","unstructured":"Zucali, P. A. et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 37, 543\u2013558 (2011).","journal-title":"Cancer Treat Rev"},{"key":"BFsrep06152_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.6004\/jnccn.2012.0007","volume":"10","author":"MG Zauderer","year":"2012","unstructured":"Zauderer, M. G. & Krug, L. M. Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw 10, 42\u201347 (2012).","journal-title":"J Natl Compr Canc Netw"},{"key":"BFsrep06152_CR9","doi-asserted-by":"publisher","first-page":"513580","DOI":"10.5402\/2012\/513580","volume":"2012","author":"JS Yakisich","year":"2012","unstructured":"Yakisich, J. S. An Algorithm for the Preclinical Screening of Anticancer Drugs Effective against Brain Tumors. ISRN Pharmacol 2012, 513580 (2012).","journal-title":"ISRN Pharmacol"},{"key":"BFsrep06152_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrd1635","volume":"4","author":"A Kamb","year":"2005","unstructured":"Kamb, A. What's wrong with our cancer models? Nat Rev Drug Discov 4, 161\u2013165 (2005).","journal-title":"Nat Rev Drug Discov"},{"key":"BFsrep06152_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2174\/156652309789753392","volume":"9","author":"PR Lowenstein","year":"2009","unstructured":"Lowenstein, P. R. & Castro, M. G. Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther 9, 368\u2013374 (2009).","journal-title":"Curr Gene Ther"},{"key":"BFsrep06152_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1476-5381.2012.01873.x","volume":"166","author":"RE Favoni","year":"2012","unstructured":"Favoni, R. E., Daga, A., Malatesta, P. & Florio, T. Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. Br J Pharmacol 166, 532\u2013553 (2012).","journal-title":"Br J Pharmacol"},{"key":"BFsrep06152_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nrc2192","volume":"7","author":"KK Frese","year":"2007","unstructured":"Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nat Rev Cancer 7, 645\u2013658 (2007).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep06152_CR14","doi-asserted-by":"crossref","unstructured":"Abolhassani, M. et al. Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice. Invest New Drugs (2011).","DOI":"10.1007\/s10637-011-9692-7"},{"key":"BFsrep06152_CR15","first-page":"448","volume":"129","author":"JE Craighead","year":"1987","unstructured":"Craighead, J. E., Akley, N. J., Gould, L. B. & Libbus, B. L. Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Pathol 129, 448\u2013462 (1987).","journal-title":"Am J Pathol"},{"key":"BFsrep06152_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.lungcan.2010.12.020","volume":"71","author":"Y Shi","year":"2011","unstructured":"Shi, Y. et al. Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model. Lung Cancer 71, 370\u2013371 (2011).","journal-title":"Lung Cancer"},{"key":"BFsrep06152_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0003-4975(95)00507-H","volume":"60","author":"JC Kucharczuk","year":"1995","unstructured":"Kucharczuk, J. C. et al. Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer. Ann Thorac Surg 60, 593\u2013597; discussion 597\u2013598 (1995).","journal-title":"Ann Thorac Surg"},{"key":"BFsrep06152_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jtcvs.2005.08.012","volume":"131","author":"D Lardinois","year":"2006","unstructured":"Lardinois, D. et al. Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. J Thorac Cardiovasc Surg 131, 697\u2013703 (2006).","journal-title":"J Thorac Cardiovasc Surg"},{"key":"BFsrep06152_CR19","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ejcts.2007.01.047","volume":"31","author":"I Opitz","year":"2007","unstructured":"Opitz, I. et al. Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment. Eur J Cardiothorac Surg 31, 773\u2013778 (2007).","journal-title":"Eur J Cardiothorac Surg"},{"key":"BFsrep06152_CR20","doi-asserted-by":"crossref","unstructured":"Zhong, J., Lardinois, D., Szilard, J., Tamm, M. & Roth, M. Rat mesothelioma cell proliferation requires p38delta mitogen activated protein kinase and C\/EBP-alpha. Lung Cancer (2011).","DOI":"10.1016\/j.lungcan.2010.12.003"},{"key":"BFsrep06152_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/sj.bjc.6605501","volume":"102","author":"JE Nutt","year":"2010","unstructured":"Nutt, J. E. et al. The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. Br J Cancer 102, 553\u2013560 (2010).","journal-title":"Br J Cancer"},{"key":"BFsrep06152_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cllc.2012.03.011","volume":"14","author":"SC Kao","year":"2013","unstructured":"Kao, S. C. et al. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales dust diseases board. Clin Lung Cancer 14, 70\u201377 (2013).","journal-title":"Clin Lung Cancer"},{"key":"BFsrep06152_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/BF02618032","volume":"17","author":"JF Aronson","year":"1981","unstructured":"Aronson, J. F. & Cristofalo, V. J. Culture of epithelial cells from the rat pleura. In Vitro 17, 61\u201370 (1981).","journal-title":"In Vitro"},{"key":"BFsrep06152_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1023\/A:1007483806960","volume":"14","author":"E Bermudez","year":"1998","unstructured":"Bermudez, E., Libbus, B. & Mangum, J. B. Rat pleural mesothelial cells adapted to serum-free medium as a model for the study of growth factor effects. Cell Biol Toxicol 14, 243\u2013251 (1998).","journal-title":"Cell Biol Toxicol"},{"key":"BFsrep06152_CR25","doi-asserted-by":"publisher","first-page":"L859","DOI":"10.1152\/ajplung.00162.2003","volume":"286","author":"WA Swain","year":"2004","unstructured":"Swain, W. A., O'Byrne, K. J. & Faux, S. P. Activation of p38 MAP kinase by asbestos in rat mesothelial cells is mediated by oxidative stress. Am J Physiol Lung Cell Mol Physiol 286, L859\u2013865 (2004).","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"BFsrep06152_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fonc.2014.00040","volume":"4","author":"M McDermott","year":"2014","unstructured":"McDermott, M. et al. In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. Front Oncol 4, 40 (2014).","journal-title":"Front Oncol"},{"key":"BFsrep06152_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/1476-4598-9-314","volume":"9","author":"A Shukla","year":"2010","unstructured":"Shukla, A. et al. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer 9, 314 (2010).","journal-title":"Mol Cancer"},{"key":"BFsrep06152_CR28","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/onc.2010.643","volume":"30","author":"CM Goparaju","year":"2011","unstructured":"Goparaju, C. M. et al. Onconase mediated NFKbeta downregulation in malignant pleural mesothelioma. Oncogene 30, 2767\u20132777 (2011).","journal-title":"Oncogene"},{"key":"BFsrep06152_CR29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1172\/JCI117388","volume":"94","author":"M Dabholkar","year":"1994","unstructured":"Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J. & Reed, E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94, 703\u2013708 (1994).","journal-title":"J Clin Invest"},{"key":"BFsrep06152_CR30","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1158\/0008-5472.CAN-03-3363","volume":"64","author":"JD Davidson","year":"2004","unstructured":"Davidson, J. D. et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64, 3761\u20133766 (2004).","journal-title":"Cancer Res"},{"key":"BFsrep06152_CR31","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4236\/jct.2013.46119","volume":"4","author":"T Obata","year":"2013","unstructured":"Obata, T., Tanaka, M., Suzuki, Y. & Sasaki, T. The Role of Thymidylate Synthase in Pemetrexed-Resistant Malignant Pleural Mesothelioma Cells. Journal of Cancer Therapy 4, 1052\u20131059 (2013).","journal-title":"Journal of Cancer Therapy"},{"key":"BFsrep06152_CR32","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1038\/sj.onc.1206953","volume":"22","author":"GD Kruh","year":"2003","unstructured":"Kruh, G. D. & Belinsky, M. G. The MRP family of drug efflux pumps. Oncogene 22, 7537\u20137552 (2003).","journal-title":"Oncogene"},{"key":"BFsrep06152_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0027-5107(01)00141-5","volume":"478","author":"M Kartalou","year":"2001","unstructured":"Kartalou, M. & Essigmann, J. M. Mechanisms of resistance to cisplatin. Mutat Res 478, 23\u201343 (2001).","journal-title":"Mutat Res"},{"key":"BFsrep06152_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5858\/arpa.2011-0215-RA","volume":"136","author":"D Jean","year":"2012","unstructured":"Jean, D., Daubriac, J., Le Pimpec-Barthes, F., Galateau-Salle, F. & Jaurand, M. C. Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med 136, 277\u2013293 (2012).","journal-title":"Arch Pathol Lab Med"},{"key":"BFsrep06152_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000356874","volume":"86","author":"T Iwanami","year":"2014","unstructured":"Iwanami, T. et al. Clinical significance of epithelial-mesenchymal transition-associated markers in malignant pleural mesothelioma. Oncology 86, 109\u2013116 (2014).","journal-title":"Oncology"},{"key":"BFsrep06152_CR36","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1023\/A:1012292230480","volume":"12","author":"Y Soini","year":"2001","unstructured":"Soini, Y., Jarvinen, K., Kaarteenaho-Wiik, R. & Kinnula, V. The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. Ann Oncol 12, 1239\u20131245 (2001).","journal-title":"Ann Oncol"},{"key":"BFsrep06152_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2174\/138945011795378540","volume":"12","author":"S Shukla","year":"2011","unstructured":"Shukla, S., Ohnuma, S. & Ambudkar, S. V. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets 12, 621\u2013630 (2011).","journal-title":"Curr Drug Targets"},{"key":"BFsrep06152_CR38","first-page":"14","volume":"1","author":"LR Chirieac","year":"2011","unstructured":"Chirieac, L. R. et al. The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura. Am J Cancer Res 1, 14\u201324 (2011).","journal-title":"Am J Cancer Res"},{"key":"BFsrep06152_CR39","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3892\/or.2013.2225","volume":"29","author":"E Yamaki","year":"2013","unstructured":"Yamaki, E. et al. Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype. Oncol Rep 29, 932\u2013940 (2013).","journal-title":"Oncol Rep"},{"key":"BFsrep06152_CR40","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-08-2023","volume":"69","author":"NA Dallas","year":"2009","unstructured":"Dallas, N. A. et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69, 1951\u20131957 (2009).","journal-title":"Cancer Res"},{"key":"BFsrep06152_CR41","doi-asserted-by":"crossref","unstructured":"Guillot, F. et al. Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth. Vaccine (2011).","DOI":"10.1016\/j.vaccine.2011.05.029"},{"key":"BFsrep06152_CR42","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/ijc.25813","volume":"129","author":"A Thomas-Schoemann","year":"2011","unstructured":"Thomas-Schoemann, A. et al. Bystander effect of vinorelbine alters antitumor immune response. Int J Cancer 129, 1511\u20131518 (2011).","journal-title":"Int J Cancer"},{"key":"BFsrep06152_CR43","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jprot.2011.11.005","volume":"75","author":"VC Hodgkinson","year":"2012","unstructured":"Hodgkinson, V. C. et al. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta\/tau and tBID? J Proteomics 75, 1276\u20131283 (2012).","journal-title":"J Proteomics"},{"key":"BFsrep06152_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1471-2407-11-64","volume":"11","author":"J Kitayama","year":"2011","unstructured":"Kitayama, J., Yasuda, K., Kawai, K., Sunami, E. & Nagawa, H. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer 11, 64 (2011).","journal-title":"BMC Cancer"},{"key":"BFsrep06152_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/172460080401900208","volume":"19","author":"P Lissoni","year":"2004","unstructured":"Lissoni, P. et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 19, 135\u2013140 (2004).","journal-title":"Int J Biol Markers"},{"key":"BFsrep06152_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55\u201363 (1983).","journal-title":"J Immunol Methods"},{"key":"BFsrep06152_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/PAT.0b013e32834642da","volume":"43","author":"SC Kao","year":"2011","unstructured":"Kao, S. C. et al. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology 43, 313\u2013317 (2011).","journal-title":"Pathology"},{"key":"BFsrep06152_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2006.08.010","volume":"38","author":"NG Ordonez","year":"2007","unstructured":"Ordonez, N. G. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 38, 1\u201316 (2007).","journal-title":"Hum Pathol"},{"key":"BFsrep06152_CR49","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/labinvest.2009.140","volume":"90","author":"Q Hu","year":"2010","unstructured":"Hu, Q. et al. Homozygous deletion of CDKN2A\/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab Invest 90, 360\u2013373 (2010).","journal-title":"Lab Invest"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep06152","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep06152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep06152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T08:06:57Z","timestamp":1672992417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep06152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,21]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,17]]}},"alternative-id":["BFsrep06152"],"URL":"https:\/\/doi.org\/10.1038\/srep06152","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,21]]},"assertion":[{"value":"12 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6152"}}